Please assess the completion status of the following clinical trial:

Trial Title: Hydroquinidine Versus Placebo in Patients With Brugada Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult (at least 18 years of age)~* Informed consent form signed~* Subject affiliated to French health insurance (Sécurité Sociale)~* Type 1 Brugada syndrome either symptomatic or asymptomatic~* Not pregnant, taking oral contraceptive measure if able to procreate~* If patient with asymptomatic type 1 Brugada, electrophysiological exploration must be positive at study inclusion~* No current intake of betablocking medicine used in cardiac insufficiency (bisoprolol, carvedilol, metoprolol)~* No current myasthenia~* No current treatment with halofantrine, pentamidine, moxifloxacin~* No current treatment with some neuroleptics~* Known hypersensitivity to hydroquinidine~* Intolerance to fructose, syndrome of glucose or galactose malabsorption, deficit in sucrase isomaltase- Cardiac insufficiency~* Histories of torsades de pointe~* Intake of medicine giving torsades de pointe~Exclusion Criteria:~* Subject not fulfilling inclusion criteria~* Subject being before study entry under hydroquinidine treatment but either at a dose \> 3 capsules per day or at a dose of 1, 2 or 3 capsules per day but with a plasmatic hydroquinidine concentration \>6µmol/L or \<3 µmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hydroquinidine (Type: EXPERIMENTAL): As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
- capsules of sugar (Type: PLACEBO_COMPARATOR): As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).